On July 7, 2026, Mr. Diego Gabathuler, Chief Executive Officer of Geistlich Pharma AG, led a seven-member senior management delegation on a visit to Shandong Junxiu Biotechnology Co., Ltd. The visit focused on technical developments, product innovation, clinical applications, and market trends in China’s regenerative medicine sector.
The delegation included Mr. Isvan Galo, Chief Commercial Officer; Mr. Marco Bollier, Vice President Asia Pacific; Mr. Mirko Zingg, Vice President Strategy and Execution; Mr. Liao Ning, General Manager of Geistlich Pharma China; and other senior executives.
During the visit, the two parties exchanged views on developments in the regenerative medicine industry, with discussions covering product and technology innovation, clinical needs, market trends, and the commercialization of research and development outcomes. They also discussed the development and application of regenerative materials and related technologies for oral tissue repair.
The Geistlich Pharma management team toured Junxiu Biotech’s exhibition hall, research and development center, and manufacturing center. The delegation learned about the company’s research and development capabilities, product development, quality management, and manufacturing processes in the field of regenerative medicine, as well as the development and commercialization progress of its related products.
The visit provided both parties with a deeper understanding of each other’s business activities and technological focus. Professional discussions were also held regarding the research and development, clinical application, and industrial advancement of regenerative medical materials.
As the healthcare market and clinical needs continue to evolve, innovative applications of biomaterials for oral tissue repair, bone regeneration, and related medical fields are attracting increasing attention across the industry. Building on its proprietary technology platforms and product development capabilities, Junxiu Biotech will continue to respond to market needs, follow emerging industry trends, and promote the innovation and development of regenerative medicine technologies and products.